The estimated Net Worth of Kevin C Tang is at least $36.1 Million dollars as of 4 October 2019. Mr. Tang owns over 285,714 units of La Jolla Pharmaceutical Co stock worth over $36,074,818 and over the last 10 years he sold LJPC stock worth over $0. In addition, he makes $34,407 as Chairman of the Board at La Jolla Pharmaceutical Co.
Kevin has made over 1 trades of the La Jolla Pharmaceutical Co stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 285,714 units of LJPC stock worth $4,999,995 on 4 October 2019.
The largest trade he's ever made was buying 285,714 units of La Jolla Pharmaceutical Co stock on 4 October 2019 worth over $4,999,995. On average, Kevin trades about 15,873 units every 0 days since 2014. As of 4 October 2019 he still owns at least 5,799,810 units of La Jolla Pharmaceutical Co stock.
You can see the complete history of Mr. Tang stock trades at the bottom of the page.
kevin C. Tang serves as Chairman of the Board of the Company. Mr. Tang has more than 25 years of experience evaluating, creating and building biotechnology companies that are focused on developing treatments for life-threatening and debilitating diseases and conditions. Since 2013, Mr. Tang has served as the Chairman and Chief Executive Officer of Odonate Therapeutics, Inc., a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Mr. Tang also serves as the President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Since 2009, Mr. Tang has served as a director of Heron Therapeutics, Inc. and since 2012, has served as Chairman. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, he served as a director of Penwest Pharmaceuticals Co. In 2006, Mr. Tang co-founded Ardea Biosciences, Inc. and served as a director from inception through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, he was a director of Trimeris, Inc. From 1993 to 2001, Mr. Tang held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.
As the Chairman of the Board of La Jolla Pharmaceutical Co, the total compensation of Kevin Tang at La Jolla Pharmaceutical Co is $34,407. There are 7 executives at La Jolla Pharmaceutical Co getting paid more, with Larry G. Edwards having the highest compensation of $749,170.
Kevin Tang is 53, he's been the Chairman of the Board of La Jolla Pharmaceutical Co since 2014. There are 8 older and 3 younger executives at La Jolla Pharmaceutical Co. The oldest executive at La Jolla Pharmaceutical Co. is Robert Rosen, 64, who is the Independent Director.
Kevin's mailing address filed with the SEC is 4747 Executive Dr #510, San Diego, CA 92121, USA.
Over the last 21 years, insiders at La Jolla Pharmaceutical Co have traded over $13,460,170 worth of La Jolla Pharmaceutical Co stock and bought 11,640,515 units worth $137,250,039 . The most active insiders traders include Advisors Llcperceptive Life..., James N Topper und Woodlands Health Ventures F.... On average, La Jolla Pharmaceutical Co executives and independent directors trade stock every 63 days with the average trade being worth of $1,249,971. The most recent stock trade was executed by Craig A Johnson on 8 July 2022, trading 12,000 units of LJPC stock currently worth $47,160.
La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.
La Jolla Pharmaceutical Co executives and other stock owners filed with the SEC include: